Form 4: Regeneron's CEO Leonard Schleifer Executes Stock Sales Under 10b5-1 Plan

Regeneron's CEO, Leonard Schleifer, reports multiple transactions involving the sale and acquisition of company stock, including common stock and Class A stock, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Leonard S. Schleifer, CEO of Regeneron Pharmaceuticals, reported changes in beneficial ownership of the company's stock.
• The transactions included the sale of common stock at various prices ranging from $1,015.00 to $1,025.55 per share on June 11 and June 12, 2024.
• These sales were executed under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on February 5, 2024.
• Schleifer also reported the acquisition of 1,000 shares of Class A stock on June 12, 2024, which converts to common stock on a one-to-one basis.
• The reported transactions also involve shares held directly, indirectly through a 401(k) plan, and through trusts, including a trust for his son.
• Following the reported transactions, Schleifer directly owns 466,877 shares of common stock and indirectly owns shares through various entities.
• He also indirectly owns 14,775 derivative securities (Class A Stock) through a trust for his son and directly owns 1,710,790 derivative securities (Class A Stock).

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and do not necessarily indicate a change in the company's outlook.

Industry Context

Executive stock transactions are common and closely monitored, especially in the pharmaceutical industry, to gauge management's confidence and potential impact on stock performance. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without concerns about insider trading.

Comparison to Industry Standards

• Executive compensation and stock ownership are typical metrics compared across the pharmaceutical industry.
• Companies like Amgen (AMGN), Pfizer (PFE), and Johnson & Johnson (JNJ) also have executives who utilize 10b5-1 plans for stock transactions.
• The volume and frequency of these transactions are often compared to industry peers to assess potential market sentiment.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, depending on market perception of executive stock transactions.
• The transactions do not appear to directly impact employees, customers, suppliers, or creditors.

Key Dates